Search Results

Guardant Health, Inc., a leading precision oncology company, announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.

Guardant Health, Inc., a leading precision oncology company, announced the company will participate in the following investor conferences.

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 98,076 shares of its common stock to three new non-executive employees.

Guardant Health, Inc., a leading precision oncology company, reported financial results for the quarter ended March 31, 2024.